Regeneron Sees Infringement In Rivals' Biosimilar Eye Meds

By Jamie Lennox (June 6, 2024, 5:19 PM BST) -- Regeneron has defended the validity of its U.K. eye medicine patents in a London court amid a feud with a biosimilars specialist and its licensing partner, alleging that their plans to market an alternate version will infringe its exclusive right to produce the drug....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!